Amarin to have strong execution year ahead, says Piper Sandler
Piper Sandler analyst Yasmeen Rahimi is confident of Vascepa's path forward in the global market following Amarin's "successful" earnings call, and sees approval in the EU and China later this year, the analyst tells investors in a research note. The analyst also remains bullish on Vascepa's U.S. sales as Amarin makes headway into persistent CV risk patients and expects Phase 3 PREPARE-IT COVID-19 data from Argentina and YE21 for Phase 4 MITIGATE-IT readout from the U.S. in 2021. Rahimi made no change to her Overweight rating or $19 price target.
